drugset / Trial / NCT06058962

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962

Phase 2 Completed 52 enrolled Paxmedica
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo

Timeline

Start
2019-06-01
Primary completion
2021-01-15
Completion
2021-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject suramin Small molecule 10 mg/kg Intravenous
Subject suramin Small molecule 20 mg/kg Intravenous